SCHEMBL18990069

SCHEMBL18990069

Cn1c(Nc2ccccc2C#N)nc2c1c(=O)n(Cc1ccc(Cl)c(Cl)c1)c(=O)n2C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.61
▸ TP53 P04637 3/20 0.61
▸ HIF1A Q16665 5/20 0.61
▸ ALDH1A1 P00352 5/20 0.59
▸ PKM P14618 3/20 0.59
▸ HPGD P15428 2/20 0.59
▸ NPSR1 Q6W5P4 2/20 0.59
▸ MTHFD2 P13995 1/20 0.59
▸ TSHR P16473 2/20 0.56
▸ USP2 O75604 1/20 0.56
▸ KMT2A Q03164 3/20 0.53
▸ POLB P06746 3/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ CTDSP1 Q9GZU7 1/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ LMNA P02545 3/20 0.53
▸ STAT6 P42226 2/20 0.53
▸ GAA P10253 1/20 0.52
▸ HTT P42858 2/20 0.51
▸ CYP1A2 P05177 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19013811 0.88 KMT2A (0.52) MAPTTP53HIF1AALDH1A1PKM
SCHEMBL18990229 0.85 HIF1A (0.69) MAPTTP53HIF1AALDH1A1PKM
SCHEMBL18990162 0.84 MAPT (0.60) MAPTTP53HIF1AALDH1A1PKM
SCHEMBL18989545 0.81 MAPT (0.64) MAPTTP53HIF1AALDH1A1PKM
SCHEMBL18990106 0.81 MAPT (0.74) MAPTTP53HIF1AALDH1A1PKM
SCHEMBL18990012 0.80 MAPT (0.76) MAPTTP53HIF1AALDH1A1PKM
SCHEMBL18990456 0.80 SMN1; SMN2 (0.62) MAPTTP53HIF1AALDH1A1PKM
SCHEMBL18989991 0.80 MAPT (0.82) MAPTTP53HIF1AALDH1A1PKM
SCHEMBL18990557 0.80 MAPT (0.67) MAPTTP53HIF1AALDH1A1PKM
SCHEMBL18989609 0.79 MAPT (0.66) MAPTTP53HIF1AALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2025-01-07 — — US disclosed
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-06-28 — — US disclosed
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-06-28 — — US disclosed
US-20180370972-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2018-12-27 — — US disclosed
EP-3389664-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF Raze Therapeutics Inc. (US) 2018-10-24 — — EP disclosed
WO-2017106352-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-06-22 — — WO disclosed
WO-2017106352-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 MAPT 1028/4885TP53 2424/4885HIF1A 2295/4885
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 MAPT 1028/4885TP53 2424/4885HIF1A 2295/4885
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF MTHFD2, MTHFD1, NUDT15 MAPT 1028/4885TP53 2424/4885HIF1A 2295/4885
US-20180370972-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF MTHFD2, MTHFD1, NUDT15 MAPT 1028/4885TP53 2424/4885HIF1A 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback